Cipla’s wholly owned subsidiary in UK -- Cipla (EU) is all set to acquire an additional 13.10% stake in Cipla (Jiangsu) Pharmaceutical, a subsidiary of Cipla EU in China. Post-acquisition, Cipla EU's stake in the subsidiary, will increase to 93.10%. The cost of acquisition is $16.40 million. The object of the acquisition is to provide quality drugs and strengthen presence in China.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
